Gemcitabine and nab-paclitaxel

Small molecule

Gemcitabine and nab-paclitaxel is one of 86 small molecule programs targeting Intestinal Cancer. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intestinal CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Intestinal CancerPhase 1/Phase 2

Active, not recruiting

Pancreatic CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

MS Contin

Merck & Co.

Preclinical

1 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 5

ABI-007

Bristol-Myers Squibb

Preclinical

2 6

LDE225

Novartis

Preclinical

1 7

Sulfonylureas

Eli Lilly

Preclinical

1 8

Thiazolidinediones

Sanofi

Preclinical

1 9

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1 10

Meglitinides

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Recruiting

Intestinal Cancer

NCT07280377

Clinical

Trials by Indication[1]

Pancreatic Cancer3 trials

Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

Completed·—·Phase 1/2·NCT02358161·78 enrolled

A Study of ABTL0812 in Pancreatic Cancer

Suspended·AAbility Pharmaceuticals SL·Phase 1/2·NCT03417921·60 enrolled

Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer

Completed·CCancer Trials Ireland·Phase 2·NCT04617067·15 enrolled

Intestinal Cancer1 trial

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

Recruiting·OOncolytics Biotech·Phase 1/2·NCT07280377·122 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Gemcitabine and nab-paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gemcitabine and nab-paclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gemcitabine and nab-paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oncolytics Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: OOncolytics Biotech

Gemcitabine and nab-paclitaxel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Pancreatic Cancer3 trials

Intestinal Cancer1 trial

References

Drug Info

Quick Facts

Related News